Opipramol 1 A Pharma (Opipramol Hydrochloride)

Opipramol Hydrochloride, the active ingredient in Opipramol 1 A Pharma, is an anxiolytic presented as an oral tablet for oral use. It is employed to alleviate anxiety symptoms and related mood disturbances in adult patients. GNH USA supplies Opipramol 1 A Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Opipramol is an anxiolytic that acts on central nervous system pathways involved in anxiety and mood regulation. - Generalized Anxiety Disorder: reduces excessive worry and tension. - Somatoform Disorder: alleviates medically unexplained physical symptoms linked to anxiety. - Depressive Disorder (adjunct): improves mood and sleep when used alongside other antidepressants.

Opipramol may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Drowsiness: feeling unusually sleepy or fatigued. - Dry mouth: reduced salivation leading to discomfort. - Constipation: infrequent or difficult bowel movements. - Dizziness: light‑headed sensation, especially on standing. - Weight gain: gradual increase in body weight. - Blurred vision: temporary visual disturbances.

Serious or Rare Side Effects: - Cardiac arrhythmia: irregular heart rhythm requiring medical attention. - Severe hypotension: marked drop in blood pressure causing faintness. - Seizures: convulsive episodes in susceptible individuals. - Hepatic dysfunction: abnormal liver enzymes or hepatitis. - Agranulocytosis: dangerously low white‑blood‑cell count. - Suicidal ideation: emergence of thoughts of self‑harm.

Before initiating Opipramol therapy, consider the following safety measures. - Cardiac assessment: evaluate history of heart disease or arrhythmias. - Liver monitoring: perform baseline and periodic liver function tests. - Gradual discontinuation: taper the dose to avoid withdrawal symptoms. - Elderly caution: start at lower doses due to increased sensitivity. - Alcohol avoidance: refrain from consuming alcohol as it may enhance sedation. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Opipramol can interact with several medication classes; awareness of these interactions helps prevent adverse outcomes.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis. - Central nervous system depressants (e.g., benzodiazepines, opioids): additive sedation and respiratory depression. - Alcohol: potentiates sedative effects and impairs coordination.

Moderate Interactions (Monitor Closely): - Antihistamines: may increase drowsiness. - Anticholinergic agents: enhance dry‑mouth and constipation. - CYP450 inhibitors (e.g., fluoxetine): can raise Opipramol plasma levels. - CYP450 inducers (e.g., carbamazepine): may reduce therapeutic effect. - Antihypertensives: monitor blood pressure for additive hypotensive effect.